Oct 19, 2026 8:30am EDT Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
Sep 14, 2026 8:45am EDT Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
Aug 17, 2026 8:30am EDT Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
Jul 20, 2026 8:30am EDT Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Jun 30, 2026 8:45am EDT Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
May 18, 2026 8:45am EDT Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
